- Cardiol Therapeutics (CRDL) has appointed Dr. Paul M. Ridker, Dr. Bruce McManus, and Dr. Joseph A. Hill to its scientific advisory board
- Each new board member brings research experience in the areas of heart disease and prevention
- Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease
- Shares in Cardiol Therapeutics Inc. (CRDL) are currently down 4.48 per cent, trading at $2.77 per share
Cardiol Therapeutics (CRDL) has appointed Dr. Paul M. Ridker, Dr. Bruce McManus, and Dr. Joseph A. Hill to its scientific advisory board.
Dr. Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital (BWH) in Boston. A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine (HMS).
His primary research focus has involved inflammatory mediators of heart disease, with particular interests in biomarkers for coronary disease, “predictive” medicine, and the underlying causes and prevention of atherosclerotic disease.
Dr. McManus is Professor Emeritus, Department of Pathology and Laboratory Medicine, the University of British Columbia. He has served as CEO, Centre of Excellence for Prevention of Organ Failure (PROOF Centre), Director, UBC Centre for Heart Lung Innovation, and Scientific Director, Institute of Circulatory and Respiratory Health, CIHR.
Dr. McManus’ work relates to mechanisms, consequences, detection, and prevention of injury and aberrant repair in inflammatory diseases of the heart and blood vessels.
Dr. Hill is Professor of Internal Medicine and Molecular Biology, Chief of Cardiology at UT Southwestern Medical Center, Dallas, TX, and Director of the Harry S. Moss Heart Center. Dr. Hill’s research examines molecular mechanisms of structural, functional, metabolic, and electrophysiological remodeling in cardiac hypertrophy and heart failure.
“We are pleased to welcome distinguished thought leaders in cardiovascular medicine to our scientific advisory board,” said Cardiol’s president and CEO David Elsley. “Their expertise in cardiovascular research will provide invaluable guidance to our research and clinical programs focused on the development of novel anti-inflammatory therapies for the treatment of heart disease.”
Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease.
Shares in Cardiol Therapeutics Inc. (CRDL) are currently down 4.48 per cent, trading at $2.77 per share as of 9:46 am EST.
